HWPC(SH:688799) 智通财经网·2026-02-13 08:16Core Viewpoint - Warner Pharmaceuticals (688799.SH) reported a revenue of 1.516 billion yuan for the fiscal year 2025, reflecting a year-on-year growth of 7.26%, and a net profit attributable to shareholders of 241 million yuan, which is a significant increase of 46.95% [1] Revenue Performance - The revenue growth during the reporting period was primarily driven by increased sales of formulation products, active pharmaceutical ingredients, intermediates, and growth in technical service income [1] Profit Analysis - The increase in net profit attributable to shareholders was mainly influenced by investment income; however, the net profit excluding non-recurring gains and losses declined due to the accrual of equity incentive expenses [1] - After excluding the impact of equity incentive expenses, the net profit attributable to shareholders, adjusted for non-recurring gains and losses, was 182 million yuan, representing a year-on-year increase of 31.57% [1]